Stock Analiz

Arbutus Biopharma Corp ABUS

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$4.09Market cap $627M
Open the interactive analysis →

Arbutus Biopharma Corp (ABUS) is a healthcare company listed in the US with a market value of about $627M. In the twelve months to September 30, 2026 it had revenue of $181M and net income of $220M, a net margin of 121.2%.

Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is value (4/5); the weakest is track record (1/5).

Key numbers: a P/E of 3.6, a price to free cash flow of 2.8, 5-year revenue growth of 15% a year, a 5-year average ROIC of -46%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 126% above the current price.

About Arbutus Biopharma

Arbutus Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $15M in 2014 to $14M in 2025, a decline of about 0.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 27% over three years (dilution for shareholders). It spends 179% of revenue on research and development.

Score: 2.6 / 5

Value4/5
Future growth3/5
Track record1/5
Financial health4/5
Shareholder returns1/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year

Checks not passed

  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row
  • ROE above 15%
  • Interest covered more than 5 times

Valuation

P/E (TTM)3.6
Forward P/E139.6
P/FCF2.8
P/S3.5
P/B7.3
EV/EBITDA2.0
PEG—
Dividend yield0.00%
FCF yield35.2%
Shareholder yield0.0%
Intrinsic value vs. price+126%

Growth and quality

Revenue growth (1 yr)128.2%
Revenue growth (5 yrs, per year)15.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-528.9%
ROIC (5-yr avg.)-45.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$181M$14M$6M$18M$39M$11M$7M$6M$6M$11M$1M
Net income$220M-$34M-$70M-$73M-$69M-$76M-$64M-$154M-$57M-$84M-$384M
Free cash flow$221M-$40M-$65M-$87M-$36M-$68M-$52M-$72M-$69M-$56M-$62M
EPS (diluted)$1.13$-0.17$-0.38$-0.44$-0.46$-0.83$-1.00$-2.89$-1.21$-1.56$-7.24
Net margin121.2%-237.9%-1133.0%-401.6%-178.0%-693.9%-922.0%-2557.4%-959.8%-788.9%-25765.5%
ROIC—-39.0%-61.1%-57.2%-37.2%-33.8%-55.1%-174.7%-41.7%-47.2%-190.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $5.34, 31% above the current price; targets range from $5.34 to $5.34; the consensus rating is “none”; expected EPS is $1.03 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Arbutus Biopharma’s P/E ratio?

About 3.6, based on the last twelve months of diluted earnings per share (forward P/E about 139.6).

Is Arbutus Biopharma stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 126% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Arbutus Biopharma pay a dividend?

Not currently.

Is Arbutus Biopharma a good stock to buy?

We do not give buy or sell advice. Arbutus Biopharma scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.